Phaseline

Companies › Apogee Therapeutics

Apogee Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 2; Immunology, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
APG777
IL-4 receptor antagonist
IL4RPhase 2Atopic Dermatitis; AsthmaNov 2026
APG990–Phase 1Atopic DermatitisDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06395948APG777Phase 2Atopic DermatitisImmunologyNov 2026
NCT06920901APG777Phase 1AsthmaRespiratoryMar 2027
NCT07027527APG777Phase 1Atopic DermatitisImmunologyDec 2027
NCT07027527APG990Phase 1Atopic DermatitisImmunologyDec 2027
NCT07003425APG777Phase 2Atopic DermatitisImmunologyDec 2029

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IL4R (1)

Companies with the same targets

Guangdong Hengrui Pharmaceutical Sanofi Keymed Biosciences Co.Ltd Regeneron Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Innovent Biologics (Suzhou) Uniquity One (UNI) Jiangsu Genscend Biopharmaceutical Genrix (Shanghai) Biopharmaceutical

Companies built like this

Jiangsu Genscend Biopharmaceutical Guangdong Hengrui Pharmaceutical Genrix (Shanghai) Biopharmaceutical Prana Therapies Enveda Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.